H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Novocure to $22 from $21 and keeps a Buy rating on the shares. The analyst cites lower expenses for 2024 post the company’s Q4 report for the target bump. The firm is expecting Optune revenue growth in 2024 driven by improving fundamentals. Headwinds from negotiations with German payers have also now been resolved, which will lead to 2024 growth, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCR:
- NVCR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NovoCure’s Lung Cancer Therapy Application Accepted by FDA
- FDA accepts Novocure PMA application for TTFields therapy in NSCLC
- Novocure enrolls final patient in TRIDENT clinical trial
- Novocure sees FY23 revenue $509.3M, consensus $505.05M
